Feb 23 (Reuters) - Eli Lilly said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month ...
Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound® Zepbound patients can access all doses in either multi-dose KwikPen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results